# | Date | Analyst Firm | Upside/Downside | Price Target Change | Rating Change | Current Rating |
---|
This allows Teva to end this historical income tax issue, and to continue to focus on its commitment to the health of patients ...
Generic Victoza® is the first-ever generic GLP-1 and supports increased demand for this category of therapies in the U.S. marke...
Teva Pharmaceutical is negotiating with the DOJ to settle a lawsuit alleging it paid kickbacks through charities to boost Copax...
Corcept Therapeutics Inc. (NASDAQ: CORT) shares are trading lower Friday afternoon following a report suggesting Teva Pharmaceu...
Teva sues Corcept over mifepristone 'monopoly' for rare disorder | Reuters
https://www.reuters.com/legal/litigation/amneal-us-ftc-win-order-removing-teva-inhaler-patents-fda-list-2024-06-10/ Drugmaker A...
Barclays analyst Balaji Prasad maintains Teva Pharmaceutical Indus (NYSE:TEVA) with a Overweight and raises the price target...